# A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.

> **NCT05965089** · PHASE1 · COMPLETED · sponsor: **Arxx Therapeutics** · enrollment: 58 (actual)

## Conditions studied

- Healthy Volunteers
- Mild to Moderate Psoriasis

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** AX-202

## Key facts

- **NCT ID:** NCT05965089
- **Lead sponsor:** Arxx Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-25
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05965089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05965089, "A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05965089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*